Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials-Reference-Cited by-同舟云学术

Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials

Published:2019-07-17 Issue:23 Volume:38 Page:4503-4518
ISSN:0277-6715
Container-title:Statistics in Medicine
language:en
Short-container-title:Statistics in Medicine

Author:

Gilbert Peter B.¹²³,Zhang Yuanyuan¹,Rudnicki Erika¹,Huang Yunda¹⁴

Affiliation:

1. Vaccine and Infectious Disease DivisionFred Hutchinson Cancer Research Center Seattle Washington

2. Public Health Sciences DivisionFred Hutchinson Cancer Research Center Seattle Washington

3. Department of BiostatisticsUniversity of Washington Seattle Washington

4. Department of Global HealthUniversity of Washington Seattle Washington

Funder

National Institute of Allergy and Infectious Diseases

Publisher

Wiley

Subject

Statistics and Probability,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/sim.8310

Reference21 articles.

1. Ending the HIV–AIDS Pandemic — Follow the Science

2. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design

3. Basis and statistical design of the passive HIV‐1 antibody mediated prevention (AMP) test‐of‐concept efficacy trials;Gilbert PB;Stat Commun Infect Dis,2017

4. Asymptotic Distribution Theory and Efficiency Results for Case-Cohort Studies

5. Improved Horvitz–Thompson Estimation of Model Parameters from Two-phase Stratified Samples: Applications in Epidemiology

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of the SLAPNAP statistical learning tool to broadly neutralizing antibody HIV prevention research;iScience;2023-09

2. Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition;eBioMedicine;2023-07

3. Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition;Nature Medicine;2022-08-22

4. Simulation-Based Pharmacokinetics Sampling Design for Evaluating Correlates of Prevention Efficacy of Passive HIV Monoclonal Antibody Prophylaxis;Statistics in Biopharmaceutical Research;2021-06-28

5. Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials;EBioMedicine;2021-02